Based on the CROWN Findings, Lorlatinib Should Be the Preferred First-Line Treatment for Patients with Advanced ALK-Positive NSCLC.
Journal of thoracic oncology official publication of the International Association for the Study of Lung Cancer（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要